Volume boost, Vivo JV likely to fuel Dixon Technologies' growth

The approval of Dixon Technologies' Vivo joint venture is expected to lift production volumes, while backward integration and export opportunities could support margins and earnings growth

tsi
Representative image
Ram Prasad Sahu
4 min read Last Updated : Jul 12 2026 | 9:37 PM IST
After a delay of more than a year and a half, the government finally approved the joint venture (JV) between Dixon Technologies (Dixon) and Vivo Mobile India (Vivo). The JV, in which Dixon, the country’s largest electronic manufacturing services (EMS) player, holds a 51 per cent stake and Vivo the remaining 49 per cent, faced an extended delay due to regulatory scrutiny under Press Note 3, which requires investments from countries sharing a land border with India, such as China, to undergo additional review. 
The JV offers an opportunity to rapidly scale up volumes and its approval has therefore led to sharp upgrades to Dixon’s revenue and earnings estimates. 
While near-term upside may be limited, given that the stock, at ₹13,420, has gained 17 per cent over the past month and 29 per cent over the past three months, the JV also offers backward integration opportunities and, consequently, the potential for higher margins. 
The biggest upside from the JV is the significant increase in volumes. Vivo, which commands a 23 per cent market share in India, ended CY25 with volumes of 35 million units. 
The company expects the JV to handle about two-thirds of this volume, translating into an annual addition of around 22 million units. Given that production is expected to begin about 40 days after the approval, the full revenue and volume benefits are likely to materialise from the December quarter. 
According to the management, the JV could add ₹30,000 crore to revenue, supported by higher average selling prices than Dixon’s existing mobile portfolio. JP Morgan Research expects the JV to contribute 11 million mobile units in 2026-27 (FY27) and 22 million units each in FY28 and FY29.  
The brokerage has raised its revenue estimates by 24-39 per cent for FY27-29, while earnings per share estimates have been upgraded by a relatively lower 13–18 per cent because of the 51:49 JV structure, which results in minority interest.  
It has an overweight rating with a target price of ₹16,700, compared with ₹14,300 earlier. 
The Vivo JV could materially increase Dixon’s mobile phone volumes from 32 million to about 55 million units, creating a stable revenue stream for the mobile segment. Beyond Vivo, the EMS major also has opportunities, particularly in exports.  
Manish Choraghe of Keynote Capitals said Dixon is exploring export opportunities in Africa through its Ismartu subsidiary and through a JV with Longcheer. Continued momentum from its existing large US customer is also expected to strengthen its export revenue profile. 
Collectively, Dixon’s mobile business remains well anchored, with client stickiness and scale being its two most durable competitive advantages, he added. The brokerage has a buy rating with a target price of ₹16,608. 
Apart from higher volumes, Dixon’s focus on backward integration and expansion into specialised EMS verticals is expected to reduce cyclicality and improve margins.  
Motilal Oswal Research pointed out that the company is investing in backward integration for display and camera modules. Teena Virmani and Prerit Jain of the brokerage expect the benefits of these initiatives to start accruing from H2FY27.  
By FY28, they expect backward integration to more than offset the margin contraction arising from the end of the production linked incentive (PLI) 1.0 scheme this year. 
For the June quarter, however, the brokerage expects operating profit margins to contract by 50 basis points year-on-year to 3.3 per cent as mobile PLI incentives cease, although an improved revenue mix across segments should limit the decline. It has a target price of ₹16,100. 
Among the key growth catalysts are continued policy support for domestic electronics manufacturing, including the mobile PLI 2.0 scheme.  
Diversification into other EMS verticals such as aerospace, automotive, defence, medical and industrial electronics should also help broaden revenue streams, reduce dependence on consumer businesses and improve margins. 
Emkay Research believes Dixon’s strong return ratios, negative working capital cycle and robust cash generation justify its premium valuation. The brokerage has a buy rating with a target price of ₹15,200. 
 
   

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :VivoStock AnalysisDixonDixon Technologies

Next Story